Methods of treating aplastic anemia by administering anti-CD26 antibodies
AssigneeADIENNE Pharma & Biotech SA
InventorAntonio Francesco Di Naro
Life of this patent
Estimating the term…
Abstract
The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
Claims24
A method of treating Aplastic Anemia in a subject in need thereof, comprising administering a therapeutically effective dose of a monoclonal antibody that specifically binds human CD26 and comprises a heavy chain variable region and a light chain variable region, wherein
- (a) the heavy chain variable region comprises a VH CDR1 comprising the sequence of SEQ ID NO:
- 133, a VH CDR2 comprising the sequence of SEQ ID NO:
- 134, and a VH CDR3 comprising the sequence of SEQ ID NO:
- 1;
- and
- (b) the light chain variable region comprises a VL CDR1 comprising the sequence of SEQ ID NO:
- 129 or 131, a VL CDR2 comprising the sequence of SEQ ID NO:
- 130 or 132, and a VL CDR3 comprising the sequence of SEQ ID NO:
- 2 or 3.
A method of treating Aplastic Anemia in a subject in need thereof, comprising administering a therapeutically effective dose of an antibody produced by the hybridoma cell line deposited at CBA-ICLC of Genoa (Italy) as PD 12002, wherein the antibody specifically binds human CD26.
A method of treating Aplastic Anemia in a subject in need thereof, comprising administering a therapeutically effective dose of an antibody mixture, wherein the antibody mixture comprises or consists of the antibodies produced by the hybridoma cell line deposited at CBA-ICLC of Genoa (Italy) as PD 12002.
A method of treating Aplastic Anemia in a subject in need thereof, comprising administering a therapeutically effective dose of a monoclonal antibody, wherein
- (a) the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy and light chain variable regions comprise the three VH CDR sequences and three VL CDR sequences, respectively, of an antibody produced by the hybridoma cell line deposited at CBA-ICLC of Genoa (Italy) as PD 12002;
- and
- (b) the antibody specifically binds human CD26.
A method of treating a subject who has received haematopoietic stem cell transplantation (HSCT), comprising administering a therapeutically effective dose of a monoclonal antibody that specifically binds human CD26 and comprises a heavy chain variable region and a light chain variable region, wherein
- (a) the heavy chain variable region comprises a VH CDR1 comprising the sequence of SEQ ID NO:
- 133, a VH CDR2 comprising the sequence of SEQ ID NO:
- 134, and a VH CDR3 comprising the sequence of SEQ ID NO:
- 1;
- and
- (b) the light chain variable region comprises a VL CDR1 comprising the sequence of SEQ ID NO:
- 129 or 131, a VL CDR2 comprising the sequence of SEQ ID NO:
- 130 or 132, and a VL CDR3 comprising the sequence of SEQ ID NO:
- 2 or 3.
Dependencies are inferred from the claim text.